Applications of monoclonal antibodies for the treatment of hematological malignancies

Magdalini Migkou; Meletios A Dimopoulos; Maria Gavriatopoulou; Evangelos Terpos

doi:10.1517/14712590802650581

Abstract

1 min read

In the next few years, investigations will be concentrated on the improvement of the older mAbs, and the development of new mAbs, targeting molecules important for malignant cell cycle and survival in an attempt to further improve patient survival.

Related publications

Article2015

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

Erika Vacchelli, Jonathan Pol, Norma Bloy, Alexander Eggermont, Isabelle Cremer, Wolf H. Fridman, Jérôme Galon, Aurélien Marabelle, Holbrook E. Kohrt, Laurence Zitvogel, Guido Guido Kroemer, Lorenzo Galluzzi

Article2017

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications

Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Guido Kroemer, Aura Muntasell, Lorenzo Galluzzi

Article2015

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Aitziber Buqué, Norma Bloy, Fernando Aranda, Francesca Castoldi, Alexander Eggermont, Isabelle Cremer, Wolf H. Fridman, Jitka Fučíková, Jérôme Galon, Aurélien Marabelle, Radek Špíšek, Éric Tartour, Laurence Zitvogel, Guido Guido Kroemer, Lorenzo Galluzzi

Article2012

Trial Watch: Monoclonal antibodies in cancer therapy

Lorenzo Galluzzi, Erika Vacchelli, Wolf H. Fridman, Jérôme Galon, Catherine Sautès‐Fridman, Éric Tartour, Jessica Zucman‐Rossi, Laurence Zitvogel, Guido Guido Kroemer

Article2021

Single-cell technologies and analyses in hematopoiesis and hematological malignancies

Ignacio Campillo‐Marcos, Damiana Álvarez‐Errico, Regina A. Alandes, Elisabetta Mereu, Manel Esteller